Body Protection Compound 157, commonly abbreviated BPC-157, is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protein found in human gastric juice. It was first isolated and characterised by Predrag Sikiric and colleagues at the University of Zagreb, who have produced the majority of the preclinical research on its biological effects over the past three decades. BPC-157 is sometimes marketed as the Wolverine peptide, a reference to the Marvel character's legendary healing abilities, reflecting its documented acceleration of multiple types of tissue repair. The Wolverine blend in commercial supplement contexts typically refers to a formulation combining BPC-157 with one or more complementary healing peptides.
Mechanisms of Action
BPC-157 promotes tissue repair through several complementary mechanisms. It stimulates angiogenesis, the formation of new blood vessels, which improves nutrient and oxygen delivery to damaged tissues. It activates the VEGF pathway and NO synthesis, both of which contribute to vascular repair and tissue remodelling. It upregulates tendon fibroblast activity, accelerating the repair of tendon and ligament injuries. It reduces pro-inflammatory cytokine production, attenuating the excessive inflammation that can impede healing in chronic injuries. And it appears to interact with the nitric oxide system in ways that have both gastrointestinal protective and systemic healing effects.
Research Evidence
The preclinical evidence base for BPC-157 is extensive, with hundreds of animal studies demonstrating accelerated healing of: tendon injuries including Achilles tendon transections; muscle tears; ligament damage; bone fractures; gastrointestinal ulcers and inflammatory bowel disease models; neurological injuries including sciatic nerve damage; and corneal injuries. Study designs typically show significantly faster return to normal function in BPC-157-treated animals compared to controls. Crucially, human clinical trial data remains limited; BPC-157 is not an approved pharmaceutical in any major jurisdiction, and the translation from rodent models to human outcomes, while promising, has not been formally established through large randomised trials.
The Wolverine Blend in Practice
Commercial Wolverine blends typically combine BPC-157 with TB-500, a synthetic version of the naturally occurring peptide Thymosin Beta-4, to address tissue repair from complementary angles. BPC-157 primarily drives angiogenesis and local fibroblast activation; TB-500 promotes actin regulation and cellular migration, which are required for tissue remodelling after initial repair. Some formulations additionally include KPV, a tripeptide fragment of alpha-MSH with anti-inflammatory properties, or GHK-Cu for its extracellular matrix remodelling effects. The rationale for combining these peptides is synergistic action on different stages of the healing cascade.
Applications and Safety Profile
BPC-157 has been studied primarily for musculoskeletal injuries, gastrointestinal conditions, and recovery from overtraining. It appears to have a favourable safety profile in animal studies, with no significant adverse effects reported even at supraphysiological doses. It does not appear to be hormonal or androgenic. The primary administration routes in research are subcutaneous or intramuscular injection near the site of injury, or oral administration for gastrointestinal applications. Oral BPC-157 appears to retain bioactivity, which is unusual for a peptide and may relate to its gastric acid origin. Anyone considering BPC-157 should source from verified suppliers and ideally work under the guidance of a practitioner familiar with peptide protocols.